» Articles » PMID: 12582450

Therapeutic Approaches to the Treatment of Alzheimer's Disease

Overview
Specialty Pharmacology
Date 2003 Feb 13
PMID 12582450
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease is the most common cause of progressive decline of cognitive function in aged humans and is characterized by the presence of numerous senile plaques and neurofibrillary tangles accompanied by neuronal loss. The only treatment currently available for the disease is pharmacotherapy with acetylcholinesterase inhibitors, a palliative strategy aimed at the temporary improvement of cognitive function. Other strategies with disease-modifying potential may include the use of antiinflammatory drugs, estrogen replacement therapy and antioxidants. Recent progress in understanding the molecular and cellular pathophysiology of Alzheimer's disease has suggested possible pharmacological interventions that could modify the development and progress of the disease (disease-modifying therapy), such as treatment with secretase inhibitors, transition metal chelators, HMG-CoA reductase inhibitors and amyloid-b immunization. Inhibitors of tau hyperphosphorylation may also modulate the development and progress of the disease.

Citing Articles

A novel rhamnoside derivative PL402 up-regulates matrix metalloproteinase 3/9 to promote Aβ degradation and alleviates Alzheimer's-like pathology.

Hu T, Zhou Y, Lu J, Xia P, Chen Y, Cao X Aging (Albany NY). 2020; 12(1):481-501.

PMID: 31901901 PMC: 6977668. DOI: 10.18632/aging.102637.


Overexpression of Ubiquilin-1 Alleviates Alzheimer's Disease-Caused Cognitive and Motor Deficits and Reduces Amyloid-β Accumulation in Mice.

Adegoke O, Qiao F, Liu Y, Longley K, Feng S, Wang H J Alzheimers Dis. 2017; 59(2):575-590.

PMID: 28598849 PMC: 5791527. DOI: 10.3233/JAD-170173.


Exercise-induced noradrenergic activation enhances memory consolidation in both normal aging and patients with amnestic mild cognitive impairment.

Segal S, Cotman C, Cahill L J Alzheimers Dis. 2012; 32(4):1011-8.

PMID: 22914593 PMC: 3951984. DOI: 10.3233/JAD-2012-121078.


ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders.

Rueter L, Anderson D, Briggs C, Donnelly-Roberts D, Gintant G, Gopalakrishnan M CNS Drug Rev. 2004; 10(2):167-82.

PMID: 15179445 PMC: 6741767. DOI: 10.1111/j.1527-3458.2004.tb00011.x.